Is Regeneron Pharmaceuticals (NASDAQ:REGN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Regeneron Pharmaceuticals at current levels.
Dupixent's global dominance and a deep late-stage pipeline make REGN a rare large-cap biotech trading below its growth rate.
Where REGN is headed
Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the few $75B biotechs that actually earns its valuation through product revenue rather than hype. At 13.2x forward earnings with 16% earnings growth ahead, this is a company the market is treating like a mature pharma name when the pipeline tells a completely different story. By late 2027, Dupixent should be running at over $16B in global sales (up from roughly $14B trailing) as new indications in COPD and chronic spontaneous urticaria layer on top of the atopic dermatitis and asthma base. EYLEA 8mg is winning the reformulation war in retinal disease, extending dosing intervals and defending a franchise that competitors like Roche's faricimab have been unable to meaningfully dent. And then there's the stuff that doesn't show up in today's revenue: the obesity partnership with Hansoh (HS-20094, a dual GLP-1/GIP agonist), the Alnylam RNAi collaboration targeting ocular and CNS diseases, and a bispecific antibody oncology portfolio that's generating real clinical data.
Read the full Compass Direction on REGN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios.
See the full REGN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Regeneron Pharmaceuticals (NASDAQ:REGN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Regeneron Pharmaceuticals at current levels. Dupixent's global dominance and a deep late-stage pipeline make REGN a rare large-cap biotech trading below its growth rate.
What is REGN's Compass Score?
Regeneron Pharmaceuticals scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for REGN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the REGN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.